Abbott Laboratories Corporation

Isa K Mushahwar

Suresh M Desai

Thomas P Leary

John N Simons

George J Dawson

Tami J Pilot-Matias

Anthony Scott Muerhoff

James Carl Erker

George G Schlauder

Sheri L Buijk

Larry G Birkenmeyer

Paul F Coleman

A Scott Muerhoff

Michelle Chalmers

Dominique P Bridon

Ronald L Marshall

Richard H Decker

Robert J Carrick

Cynthia Jou

Mark F Knigge

Keeve D Jaffe

Teresa K Surowy

Pamella A Schroeder-Poliak

Karen V Stuckmann

Scott Muerhoff

The subject invention relates to a novel hepatitis B surface antigen mutant and methods of detecting this mutant, and/or antibodies thereto, in patient samples. In particular, the mutant contains a substitution of amino acid threonine for the amino acid alanine at position 123 in the amino acid sequence of the hepatitis B surface antigen (HBsAg) protein.

Hepatitis B virus surface antigen mutant and methods of detection thereof

Hepatitis GB Virus (HGBV) nucleic acid and amino acid sequences useful for a variety of diagnostic and therapeutic applications, kits for using the HGBV nucleic acid or amino acid sequences, HGBV immunogenic particles, and antibodies which specifically bind to HGBV. Also provided are methods for producing antibodies, polyclonal or monoclonal, from the HGBV nucleic acid or amino acid sequences.

Non-a, non-b, non-c, non-c, non-d, non-e hepatitis reagents and methods for their use

Non-A, non-B, non-C, non-D, non-E hepatitis reagents and methods for their use

The subject invention relates to improvements in nucleic acid isolation, and more particularly, relates to modifications to the subtractive hybridization method and to reagents such as oligonucleotides that are useful when performing the method.

Method of performing subtractive hybridization using RDA

The present invention relates to nucleic oligomer primers or probes useful for detection of TTV in test samples. Also provided are assays which utilize these primers and probes, as well as test kits which contain these oligomer primers and/or probes. In addition, the present invention encompasses the use of TTV nucleotide sequences as nucleic acid vectors and as markers for determining transmission between individuals as well as the route thereof. Additionally, the present invention encompasses a method of detecting TTV infection prior to xenotransplatation of a tissue or organ.

Methods of utilizing the TT virus

Recombinantly produced hepatitis GB Virus (HGBV) amino acid sequences useful for a variety of diagnostic and therapeutic applications, kits for using the HGBV amino acid sequences and antibodies which specifically bind to HGBV. Also provided are methods for producing antibodies, polyclonal or monoclonal, from the HGBV recombinantly produced amino acid sequences.

Hepatitis GB virus recombinant proteins and uses thereof

Non-A, non-B, non-C, non-D, non-E hepatitis reagents and methods for

Hepatitus GB Virus (HGBV) nucleic acid and amino acid sequences useful for a variety of diagnostic and theraeutic applications, kits for using the HGBV nucleic acid or amino acid sequences, HGBV immunogenic particles, and antibodies which specifically bind to HGBV. Also provided are methods for producing antibodies, polyclonal or monoclonal, from the HGBV nucleic acid or amino acid sequences.

Non-A, non-B, non-C, non-D, non-E Hepatitis reagents and methods for

The present invention provides a method for quantitatively detecting the amount of a target nucleic acid sequence which may be present in a test sample. A test sample which may contain a target nucleic acid sequence comprising target sequences X and Y is contacted with two primer sets, the first set being specific for target X and the second set being specific for target Y. The test sample also is contacted at the same time with an internal standard sequence IS, which is substantially derived from a combination of the first and second target sequences, and its corresponding oligonucleotide primers. Haptens are associated with the oligonucleotide primer sets in such a way that amplified target sequence products X and Y are detected by capture on a solid phase to which anti-hapten capture reagents are attached. A signal ratio of (X+Y)/S is determined to quantitate the amount of the target nucleic acid sequence contained in the sample.

Primer compositions and kits for detecting hepatitis B virus

Reagents and composition for controlling the translation of hepatitis GB virus (HGBV)-A, -B or -C peptides from viral nucleic acid. These reagents and methods comprise control elements of the 5' NTR region of the HGBV-A, -B, or -C viral genome.

Reagents and methods useful for controlling the translation of hepatitis

A biotin-antibiotin immunoassay comprises coating a solid phase with a ligand-specific binding material, reacting the solid phase with a test sample, reacting the solid phase with the biotin-labeled form of the ligand-specific binding material and antibiotin labeled with a suitable marker. The marker is then measured to detect the amount of ligand present in the test sample.

Immunoassay for the detection of ligands

Growing community of inventors

Grayslake, IL, United States of America

Isa K Mushahwar